1. State of the Art in BRCA-Mutated Ovarian Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Ovarian Cancer

5. Case 1 Susan

6. Case 1 Susan (cont)

7. Frequency of Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer

8. Genetic Testing of Ovarian Cancer

9. Mutation Status by Histology

10. Single-Gene vs Multigene (Panel) Testing

11. Cascade Testing and Genetic Counseling

12. Genetic Testing Rates

13. Effect of BRCA Mutations in the Front Line

14. Germline vs Somatic Mutations

15. Case 2 Angela

16. Case 2 Angela (cont)

17. FDA-Approved PARP Inhibitors

18. Phase 3 PARP Inhibitor Maintenance Studies

19. PFS in Phase 3 Maintenance Studies

20. Maintenance Studies Patients in PR vs CR

21. PFS Hazard Ratio by Mutation Status

22. Case 2 Angela (cont)

23. PARP Inhibitors Safety

24. Toxicity GI and Fatigue

25. Toxicity Hematologic

26. Toxicity Other

27. Future Directions

28. Key Takeaways

29. Abbreviations

30. Abbreviations (cont)